e-learning
resources
Vienna 2012
Sunday, 02.09.2012
Asthma: assessment and treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Omalizumab in severe adult atopic dermatitis associated to mild asthma treated with omalizumab
A.A. Stanziola, M. D‘Amato, C. Vitale, M. Lanza, A. Molino, M.L. Bocchino, M. Sofia (Naples, Italy)
Source:
Annual Congress 2012 - Asthma: assessment and treatment
Session:
Asthma: assessment and treatment
Session type:
Thematic Poster Session
Number:
510
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A.A. Stanziola, M. D‘Amato, C. Vitale, M. Lanza, A. Molino, M.L. Bocchino, M. Sofia (Naples, Italy). Omalizumab in severe adult atopic dermatitis associated to mild asthma treated with omalizumab. Eur Respir J 2012; 40: Suppl. 56, 510
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Omalizumab in children with severe persistent allergic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Omalizumab, a novel therapy for severe allergic asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 37s
Year: 2001
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Source: Eur Respir J 2002; 20: 73-78
Year: 2002
Efficacy of omalizumab in patients with concomitant allergic asthma and atopic dermatitis: a pilot study
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia
Source: Eur Respir J 2014; 44: 239-241
Year: 2014
Assesment of long-term omalizumab treatment in severe allergic asthma
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Treatment of co-morbid allergic asthma and perennial allergic rhinitis with the anti-IgE agent omalizumab
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 663s
Year: 2006
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017
Immunotherapy in severe asthma
Source: ERS webinar 2021: Immunotherapy in severe asthma
Year: 2021
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Omalizumab decreases IgE production in patients with severe allergic asthma
Source: Annual Congress 2012 - Aspects of clinical asthma
Year: 2012
Follow-up of patients with moderate-severe allergic asthma treated with omalizumab
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010
Real-life long-term omalizumab therapy in children with severe allergic asthma
Source: Eur Respir J 2015; 46: 856-859
Year: 2015
Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
Combined childhood flexural eczema and rhinitis predicts atopic asthma but not non-atopic asthma
Source: Annual Congress 2010 - New insights in the epidemiology of asthma
Year: 2010
Treatment and outcomes in patients with asthma and allergic rhinitis
Source: Eur Respir J 2005; 26: Suppl. 49, 576s
Year: 2005
The evaluations of allergic rhinitis symptoms in patients with asthma and allergic rhinitis with the addiing of montelukast in asthma treatment
Source: Eur Respir J 2004; 24: Suppl. 48, 124s
Year: 2004
Staphylococcal Enterotoxins sensitization and response of Omalizumab in severe atopic and non atopic asthma
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma
Source: International Congress 2019 – Novel findings from asthma clinical trials
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept